Search

Home > Cell & Gene: The Podcast > Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset
Podcast: Cell & Gene: The Podcast
Episode:

Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset
Category: Science & Medicine
Duration: 00:24:15
Publish Date: 2021-07-08 12:00:00
Description:

During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means in the world of rare diseases. 
Total Play: 0